


Learning Objectives

- Identify the unique clinical and epidemiological characteristics of Coronavirus (COVID-19) in the spectrum of viral clinical illnesses and previous Coronavirus (SARS, MERS) and non-Coronavirus (influenza, common cold) related illnesses
- Describe the epidemiological impact of interventions to reduce spread of disease in the setting of limited healthcare resources
- Summarize common clinical presentations of COVID-19 compared to other cold and influenza related illnesses and describe who should receiving referral for testing
- Analyze emerging literature regarding potential treatment modalities for COVID-19
- Devise potential roles for pharmacists and technicians in a variety of healthcare settings for the management of a COVID-19 pandemic
- List the steps the Colorado Pharmacists Society (CPS) is taking to address COVID-19.
- Describe how CPS is collaborating with other professional pharmacy organizations and state and federal agencies.

Staggs Echold Frances and Prenetod bill Scenes







COVID-19 Myth 1: ACE/ARB Treated Patients Do Worse Because of Viral Entry ACE Protein



ACC/HFSA/ESC say do not discontinue to prevent COVID-19



Staggs Extended Francey and the twend by Service Image source amazon

Few differences in#


with mild vs severe

disease


hypertensive patients

Why Is COVID-19 So Clinically Relevant?

COVID-19 Has a Basic Reproduction (Ro) number of 2-3







	SARS CoV	MERS CoV	SARS-CoV 2		
Virion Structure	Enveloped RNA virus	Enveloped RNA virus	Enveloped RNA virus		
Outbreak period	2003-2004	2012-present	Dec 2019-present		
Initial site of isolation	Guangdong province, China	Saudi Arabia	Wuhan, China		
No. of countries/cases	29	27	>70		
No. of cases (mortality)	8,096 (9.6%)	2,494 (~34%)	~109,936 (N=3,806)(3.4%)*		
No. of cases U.S.	8	2 (2014)	538 (WA, IL, CA, AZ, Mass, Wis		
Reservoir (intermediate host)	Bats (palm civet)	Bats (dromedary camels)	Bats (likely a zoonosis)		
Incubation period	2-7 days (range, 2-21)	2-7 (range, 2-14 days)	2-14 days (mean 5-6)		
Infectivity, rho	1.8-2.5	0.3-1.3	~3 (2.4-3.8)*		
Super spreaders	Yes	Yes (common)	Yes (many examples)		
Asymptomatic/mild Spread	No	Rare	Yes/Yes		
Attack Rate	10.3% to 60%	4 to 20%	20-30%, 80% (early study)?		
Transmission (including to HCP)	Droplet/Direct, Airborne/Indirect?	Droplet/Direct, Airborne/Indirect?	Droplet/Direct, Airborne/Indirect/Fecal		
Treatment (PEP)	Supportive (none)	Supportive (none)	Supportive (drugt CU)		
Infection Prevention	Airborne, contact, face	Airborne, contact, face	Airborne, contact, face shield		

Differentia	ting Sympt	loms	
Symptom/Lab	COVID-19	Influenza	Common Cold
Fever	>80-90% – careful sometimes delayed!	>80-90%	Very Rare
Cough	70% of which majority is dry cough (30% sputum producing)	Often dry	Common – dry or wet
Myalgia/Fatigue	11-50%	Common	Rare
Immune effects	Leukopenia (30-60%) – T cell Depression	Rare	Never
Platelet effects	Thrombocytopenia (40- 60%)	Rare	Never
Sneezing	No	Rare	Common
Congestion	No	Rare	Common
Sore Throat	13%	Rare	Common
Hospitalization Rate	4-16% (ICU)	0.03%	Rare
Cause of Death	Acute Respiratory Distress Syndrome (ARDS)	ARDS	Rare

Testing for COVID-19


The Reason for Separation

Source: Medium.com

Chart 9: Total Cases of Coronavirus Outside of China (Countries with >50 cases as of 3/7/2020)

- What tests are available?
 - Standard of care: Real time rRT-PCR (Nasopharyngeal, oropharyngeal, bronchioalveolar lavage, aspirates, sputum)
 - Alternative testing (in development): IgM ELISA, Point of care testing
- Who to test?
 - At risk individuals with symptoms compatible with COVID-19
 - Hospitalized patients with symptoms compatible with COVID-19
 - Any persons (esp healthcare workers) within 14 days of close contact (from sx onset) of a confirmed COVID-19 patient
- Colorado: Mitigation strategies may go into effect












Chart 20: Excess Death in Denver during the 1918 Flu Pandemic





Source: Marginal Revolution, https://marginalrevolution.com/marginalrevolutio n/2020/03/what-worked-in-1918-1919.html












Staggs Echold France



Clinical Evidence – Hydroxychloroquine

Post-exposure prophylaxis study - HCWs:



Clinical Evidence - Lopinavir/ritonavir


SARS-CoV-1

- Chu et al. 2004: ARDS or death lower with lopinavir/ritonavir vs. ribavirin alone (2.4% vs. 29%)
 - Retrospective, imbalance in baseline characteristics between groups, lopinavir/ritonavir patients received concomitant ribavirin
- Rapid viral load decline in lopinavir/ritonavir recipients from nasopharyngeal specimens
 Chan et al. 2003: lopinavir/ritonavir plus ribavirin decreased mortality
 compared to ribavirin alone (2.3% vs. 11%, p < 0.05)
 - Matched, retrospective study. All patients received concomitant corticosteroids as well
 Rescue therapy with lopinavir/ritonavir not different from matched controls

Palesta Palesta

COLCERES FIREMACIS


 Park et al. 2019: lopinavir/ritonavir plus ribavirin effective as post-exposure prophylaxis against MERS-CoV



25


N Fee I Med 2020 Feeby PMID: 32182464


Clinical Evidence			A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19				
Baseline	demogr	aphics		Ounchride	Tursel (N = 139)	Lepinair Storerk (N-23)	Standard Care (H + 330)
			Standard Care	NEWS2 soorr at sky 1 resolves (KQR)	1040-0.0	12(23.6.8)	3.0 (4.8-7.8)
Departmenter	Tutal IN-199	Lapingvir-Ribargvir (N = 98)	Standard Care (N = 100)	Sever-category scale at day 1			
ar, median (1015 ur	38.0 (45.0 - 68.0)	58.0 (50.0-68.m)	38.0 (48.0-48.0)	3 Hapbalanties, not requiring supplemental engine - m; [5]	28 (14.0)	11 (51.11	17.078
Advance - no. (%)	129-090.30	51 (51.6)	22 (22.0)	4 Hospitalization, requiring supplemental angent — mil (%) 8 Hospitalization, requiring VENC or numbershap methanizat	111110	11/15.0	14.04.05
peniding conditions no. (%)	mar (we sty	AT (AT V)	27 Garage	versialus - nu (N)	THE PARTY OF	10.0014	HOUSE
Didutes	23 (31-6)	10(10.3)	11(110)	6. Hospitalization, requiring EONO, invasion mechanical set-follows, at both ins. (N)	1 (0.5)	1(1.0)	
Cerebrovascular disease	13 (6.5)	\$ (5.1)	140	Das fore these anality sedemoster - mater 201	11111-10	1103.45	12 (05.00)
Dever	6/3/0	10.0	10.0	Earlier [132] date of complete areas(res. [91]	80 (45.2)	62 (52 5)	48.00.0
init invanators, market (IOR 'C	76.5 (36.4.36.8)	353 (354-37.0)	16.1 (16.1.19.8)	Later O12 days of semantism county - ms. (No	109 (54.8)	17.07.6	12 (52.9)
nuer no. (%)	182 (91.5)	89 (89.8)	\$2,022,02	Many unai had log_ copies per wist due 1	4.8+2.1	4.462.0	3.752.1
estister of states and set of the	12 (18.8)	21 (21.6)	16(16(2)	Using into favor at annal must mu (N)	20 (11.0)	9.01.11	15 (03.0)
				Teaments during study period vis. (%)			
				Vacquerracia	44 (22.1)	101012	27 (27.0)
				Recal-replacement therapy	9 (4.5)	3 (5.0)	6 (6.0)
				Renimpulse-mechanical vertilation	29(34.6)	30(08.1)	19 (58-0)
				manine resiluental sections	17(18-1)	34(843)	18.02.0
				8CMO	4 (2.0)	2(28)	2(28)
				Antibodia apeti	184 (44.10)	80 (20) FT	#5.0%.H
				Giantein kinnid #unagy	AT (\$3.7)	42 (93.3)	43 (35.4)
				Then have observe around its glacocontravid that app median (1Q4)	19102-15	19-03-09	13 (9-15)
				Days of glucocorricold therapy median (KQP)	4(0-11)	7(5-11)	8 (2-12)
ing J Med. 2020. Epub: PMID: 321874 Shapps Schoold Francus with Personal School Schools	164			* Piece minute selates an intern y 323 FOMO denotes intercorporation py, and NEWS2 Mattered Dath Wenning Scient 1.	erlena organi	e, HTRE high flow naval to	COLCENS COLCENS COLCENS



Clinical Evidence - Remdesivir
-
Appears effective against Ebola
Clinical studies lacking for SARS-CoV-2
Ongoing clinical trials
 U.S. = 3 studies (1 NIAID and 2 Gilead sponsored) China = 2 studies
Dosing – 200mg IV load, then 100mg IV daily x 5-10 days
 Safety: mostly GI and liver-related effects to date reported IV contains cyclodextrin (SBECD)
btgs://disisilisgs/cft2/rsslt/bord-&sem-sem/ou/cfkotty-&dust-&cftp-&dust-

Hyperinflammation Remdesivir Compassionate use available (https://rdvcu.gilead.com/) Subset of COVID-19 progress to hyperinflammatory state GILEAD High, persistent fever Cvtopenias The following patient criteria must o Hyperferritinemia Key Inclusion oriteria Increased IL-6, CRP, and d-dimer Hospitalization Confirmed SARS-CoV-2 by PCR Invasive (ie intubated or Tracheos Screening – Hscore for probability of Kev Exclusion criteria: secondary HLH · Evidence of Multi-organ failu Pressor regulrement to maintain blood pressure Immunosuppression - tocilizumab






Clinical Evidence - Others Nitazoxanide – in vitro only to date Interferon – in vitro and limited clinical experience from SARS-COV-1 and MERS-COV (combined with other agents) Statins – anti-inflammatory mechanism – theoretical presently and no published evidence of direct benefit for COVID-19 VIG – not expected to be effective, pooled sources unlikely to have any sufficient anti-SARS-CoV-2 neutralizing antibodies Corticosteroids – unclear role, likely beneficial during later stages of infection where inflammatory response increased







What is CPS doing?
 Letter to the governor asking for emergency measures (sent March 13th) Remote pharmacy practice – remove requirements for prior board approval Allow 90 day supplies of chronic medications Extend technician certification deadlines Allow the CMO of CDPHE to allow pharmacists to provide designated services for: Testing Screening Prescribing (standing order or CPA)

Staggs Ected of Frem and Premised of Science

What is CPS doing?

- Community forum for COVID-19
 - Childcare options for healthcare workers
 - Clinical trial information (post-COVID exposure prophylaxis)
- Dedicated web page
- Social media posts (follow us!)

Shapps Echold Francey and Frances of tel Sonces

National professional organizations

- NACDS policy requests (partial list)
 - In anticipation of a COVID-19 vaccine, making sure pharmacists may access and immunize without barriers
 - Allowing pharmacists and techs to work across state lines
 - Broader prescriptive authority for mild ailments
 - Allowing remote verification of prescriptions

▶NASPA

Regular communication regarding activities in other states

Staggs Echold Francoy and Protected to Start De 